These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 15170969)

  • 1. [Medical problems associated with the national reference pricing system in Hungary].
    Kerpel-Fronius S
    Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
    Kaló Z; Muszbek N; Bodrogi J; Bidló J
    Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reimbursement of generics in Croatia: should more have been done?].
    Vukusić M
    Lijec Vjesn; 2010; 132(5-6):134-43. PubMed ID: 20677618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
    Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
    Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reference-based pricing in British Columbia: implications for cardiologists--an analysis.
    Boulet AP; Tessier G
    Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pricing and reimbursement of drugs in Denmark.
    Møller Pedersen K
    Eur J Health Econ; 2003; 4(1):60-5. PubMed ID: 15609170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vision of the pharmaceutical industry.
    Muñio S
    Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():5-9. PubMed ID: 9800720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pricing and reimbursement of drugs in Sweden.
    Lundkvist J
    Eur J Health Econ; 2002; 3(1):66-70. PubMed ID: 15609120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of the pharmaceutical expenditure in Hungary].
    Inotai A; Merész G; Kaló Z
    Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of reference-pricing systems in Europe: a literature review and case studies.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):729-37. PubMed ID: 22098289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Priorisation in health-care; drug-reimbursement priorities in Hungary in 2004].
    Kárpati K; Brandtmüller A; Májer I; Gulácsi L
    Acta Pharm Hung; 2006; 76(4):191-9. PubMed ID: 17575799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of prescription pricing and a call for equitable payment.
    Grapes ZT; Brown TR
    Hospitals; 1976 Jul; 50(13):91-2, 96, 98. PubMed ID: 1278895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.